Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009

BMC Infectious Diseases

Eric L Matteson¹  Robert Orenstein¹  Glenn D Roberts¹  Cynthia S Crowson¹  Tim Bongartz¹  Timothy C Olson¹ 

[1] From the Department of Internal Medicine (TCO), Division of Rheumatology (TB, ELM, Division of Biomedical Statistics and Informatics (CSC), Department of Laboratory Medicine and Pathology (GDR), and Division of Infectious Diseases (RO), Mayo Clinic College of Medicine, Rochester, Minnesota, 55905, USA

关键词: rheumatoid arthritis;    Histoplasmosis;   

Others  :  1175704
DOI  :  10.1186/1471-2334-11-145

 received in 2010-11-21, accepted in 2011-05-23,  发布年份 2011

【 摘 要 】

Background

Patients with rheumatic diseases including rheumatoid arthritis (RA) are at increased risk for infections related to both the disease and its treatments. These include uncommonly reported infections due to histoplasmosis.

Methods

Medical record review of all patients with a diagnosis of RA who developed new histoplasmosis infection in an endemic region between Jan 1, 1998 and Jan 30, 2009 and who were seen at Mayo Clinic in Rochester, Minnesota was performed.

Results

Histoplasmosis was diagnosed in 26 patients. Most patients were on combination therapies; 15 were on anti-tumor necrosis factor (anti-TNF) agents, 15 on corticosteroids and 16 on methotrexate. Most received more than 6 months of itraconazole and/or amphotericin treatment. Two patients died of causes unrelated to histoplasmosis. Anti-TNF treatment was restarted in 4/15 patients, with recurrence of histoplasmosis in one.

Conclusions

In this largest single center series of patients with RA and histoplasmosis in the era of immunomodulatory therapy, we found that most patients had longstanding disease and were on multiple immunomodulatory agents. Most cases were pulmonary; typical signs and symptoms of disease were frequently lacking.

【 授权许可】

   
2011 Olson et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL: Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983, 62(5):263-70.
• [2]Deepe GS Jr: Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 2005, 41(Suppl 3):S204-7.
• [3]Kauffman CA: Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007, 20(1):115-32.
• [4]Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-5.
• [5]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criterial for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-24.
• [6]Wheat LJ, Kohler RB, Tewari RP: Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986, 314(2):83-8.
• [7]Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat JL: Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010, 50(1):85-92.
• [8]Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP: Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83(2):181-94.
• [9]Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC: Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007, 86(3):162-9.
• [10]Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL: Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003, 167(9):1279-82.
• [11]Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-85.
• [12]Rychly DJ, DiPiro JT: Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005, 25(9):1181-92.
• [13]Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46(10):2565-70.
• [14]FDA: Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). [http:/ / www.fda.gov/ Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforP atientsandProviders/ ucm124185.htm] webciteFDA ALERT 2008.
• [15]Jain VV, Evans T, Peterson MW: Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 2006, 100(7):1291-3.
• [16]Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M: Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002, 4(3):148-51.
• [17]Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(7):807-25.
• [18]Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C: Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30(4):688-95.
• [19]Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W: Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(2):100-7.